| Company Name: |
Chunchuang (Wuhan) Technology Co., Ltd
|
| Tel: |
15727060112 |
| Email: |
yutianchun2007@126.com |
| Products Intro: |
Product Name:Methanesulfonamide, N-[[1-[6-(trifluoromethyl)-4-quinazolinyl]-3-piperidinyl]methyl]-
CAS:2322245-42-9
Purity:99.5+ Package:1g/RMB 1000
|
Methanesulfonamide, N-[[1-[6-(trifluoromethyl)-4-quinazolinyl]-3-piperidinyl]methyl]- manufacturers
- SRI-37330
-
- $42.00
-
2026-07-15
- CAS:2322245-42-9
- Purity: 99.65%
- Supply Ability: 10g
|
| | Methanesulfonamide, N-[[1-[6-(trifluoromethyl)-4-quinazolinyl]-3-piperidinyl]methyl]- Basic information |
| | Methanesulfonamide, N-[[1-[6-(trifluoromethyl)-4-quinazolinyl]-3-piperidinyl]methyl]- Chemical Properties |
| Boiling point | 524.2±60.0 °C(Predicted) | | density | 1.371±0.06 g/cm3(Predicted) | | storage temp. | 4°C, stored under nitrogen | | solubility | DMSO : 100 mg/mL (257.46 mM; Need ultrasonic) | | form | Solid | | pka | 11.14±0.40(Predicted) | | color | White to off-white |
| | Methanesulfonamide, N-[[1-[6-(trifluoromethyl)-4-quinazolinyl]-3-piperidinyl]methyl]- Usage And Synthesis |
| Description | SRI-37330 is a novel inhibitor of TXNIP expression, decreasing glucagon secretion and action and blocking hepatic glucose output, reversing obesity- and STZ-induced diabetes and hepatic steatosis. | | Uses | SRI-37330 is an orally bioavailable thioredoxin-interacting protein (TXNIP) inhibitor. SRI-37330 inhibits glucagon secretion and function, reduces hepatic glucose production and reverses hepatic steatosis. SRI-37330 can be used for type 2 diabetes research[1]. | | in vivo | SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) decreases glucagon secretion and action and blocks hepatic glucose output[1].
SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) is well tolerated in male C57BL/6J mice[1].
SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) reverses obesity- and STZ-induced diabetes and hepatic steatosis in mice[1].
| Animal Model: | C57BL/6J mice[1] | | Dosage: | 100 mg/kg | | Administration: | Oral administration (p.o.), in drinking water, 3 weeks. | | Result: | Lowered serum glucagon levels, inhibited hepatic glucose production and improved glucose homeostasis in mice. |
| | References | [1] Thielen LA, et al. Identification of an Anti-diabetic, Orally Available Small Molecule that Regulates TXNIP Expression and Glucagon Action. Cell Metab. 2020 Sep 1;32(3):353-365.e8. DOI:10.1016/j.cmet.2020.07.002 |
| | Methanesulfonamide, N-[[1-[6-(trifluoromethyl)-4-quinazolinyl]-3-piperidinyl]methyl]- Preparation Products And Raw materials |
|